- *SARCLISA + Pd significantly increased mPFS vs. Pd alone (11.53 vs. 6.47 months, HR 0.596 [95% CI 0.44, 0.81]; p=0.001).2
patients who may benefit from SARCLISA combination therapy
the SARCLISA + Pd (ICARIA-MM) efficacy results
SARCLISA, an anti-CD38 mAb with multimodal anti-tumour action
SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.